摘要
[目的]探讨利拉鲁肽应用在2型糖尿病合并非酒精性脂肪肝病中的临床疗效及应用价值。[方法]将我院治疗的2型糖尿病合并非酒精性脂肪肝病患者152例采用随机数字法分为观察组和对照组,每组各76例,对照组给予二甲双胍治疗,观察组联合利拉鲁肽治疗,记录2组治疗效果。[结果]观察组治疗后甘油三酯(1.39±0.13)mmol/L,总胆固醇(4.19±0.27)mmol/L,低密度脂蛋白(2.43±0.18)mmol/L;对照组治疗后甘油三酯(1.97±0.42)mmol/L,总胆固醇(5.76±0.53)mmol/L,低密度脂蛋白(2.94±0.44)mmol/L,组间比较差异有统计学意义(P<0.05)。观察组治疗后胰岛素抵抗指数(2.31±0.14),超声分数(2.23±0.31)分;对照组治疗后胰岛素抵抗指数(2.84±0.39),超声分数(3.19±0.63)分,组间对比差异有统计学意义(P<0.05)。观察组治疗后ALT(13.24±3.67)U/L,AST(32.09±4.11)U/L;对照组治疗后ALT(63.67±13.14)U/L,AST(55.34±11.45)U/L,组间对比差异有统计学意义(P<0.05)。[结论]利拉鲁肽应用在2型糖尿病合并非酒精性脂肪肝病能够有效改善患者血脂浓度,减轻胰岛素抵抗和非酒精性脂肪肝肝损伤,保护患者肝脏功能,值得在临床上推广应用。
[Objective] To discuss Liraglutide used in type 2 diabetes mellitus and nonalcoholic fatty liver disease in the clinical curative effect and application value. [Methods]152 patients with type 2 diabetes mellitus treated with nonalcoholic fatty liver disease were randomly divided into observation group and control group. 76 cases in each group and control group were treated with metformin. The observation group was treated with liraglutide, Two groups of treatment effects were recorded. I-Results]Observation group after treatment triglycerides （ 1.39± 0. 13） tendency/L, total cholesterol （4.19 ±0. 27） tendency for L, low density lipoprotein （2.43±0.18） tendency/L; The control group after treatment triglycerides （ 1.97 ± 0.42） tendency/L, total cholesterol（5.76 ±0.53） tendency for L, low density lipoprotein （ 2.94± 0.44） tendency for L, the differences between groups was statistically significant（P〈0.05）. Observation group after treatment of insulin resistance index（2. 31±0.14）,ultrasonic score（2.23±0.31）;The control group after treatment of insulin resistance index（2.84±0.39）,ultrasonic score（3.19±0.63）points,the differences between groups was statistically significant（P〈0.05）. Observation group after treatment of ALT（13.24±3.67）U/ L,AST（32.09±4.11）U/L;The control group after treatment of ALT（63.67±13.14）U/L,AST（55.34±11.45） U/L, the differences between groups was statistically significant （P〈0.05）. [Conclusion] The Lira glutide used in type 2 diabetes mellitus and nonalcoholic fatty liver disease can effectively improve blood lipid concentration, reduce insulin resistance and nonalcoholic fatty liver liver damage, protect liver function in patients, is worth popularization and application in clinic.
出处
《中国中西医结合消化杂志》
CAS
2017年第3期195-198,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
关键词
利拉鲁肽
糖尿病
非酒精性脂肪肝病
Liraglutide
diabetes mellitus
nonalcoholic fatty liver
